Decuprate: Preliminary Phase II data

Preliminary data from 15 evaluable patients ages >=18 with newly diagnosed Wilson’s disease receiving once-daily oral Decuprate in the open-label, international Phase II

Read the full 231 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE